Skip to main content
Top
Published in: Journal of Neuroinflammation 1/2012

Open Access 01-12-2012 | Research

Keratinocyte expression of inflammatory mediators plays a crucial role in substance P-induced acute and chronic pain

Authors: Tzuping Wei, Tian-Zhi Guo, Wen-Wu Li, Saiyun Hou, Wade S Kingery, John David Clark

Published in: Journal of Neuroinflammation | Issue 1/2012

Login to get access

Abstract

Tibia fracture in rats followed by cast immobilization leads to nociceptive, trophic, vascular and bone-related changes similar to those seen in Complex Regional Pain Syndrome (CRPS). Substance P (SP) mediated neurogenic inflammation may be responsible for some of the signs of CRPS in humans. We therefore hypothesized that SP acting through the SP receptor (NK1) leads to the CRPS-like changes found in the rat model. In the present study, we intradermally injected rats with SP and monitored hindpaw mechanical allodynia, temperature, and thickness as well as tissue levels of tumor necrosis factor-α (TNF-α), interleukin 1β (IL-1β), interleukin 6 (IL-6), and nerve growth factor-β (NGF) for 72 h. Anti-NGF antibody was utilized to block the effects of SP-induced NGF up-regulation. Fracture rats treated with the selective NK1 receptor antagonist LY303870 prior to cast removal were assessed for BrdU, a DNA synthesis marker, incorporation in skin cells to examine cellular proliferation. Bone microarchitecture was measured using micro computed tomography (μCT). We observed that: (1) SP intraplantar injection induced mechanical allodynia, warmth and edema as well as the expression of nociceptive mediators in the hindpaw skin of normal rats, (2) LY303870 administered intraperitoneally after fracture attenuated allodynia, hindpaw unweighting, warmth, and edema, as well as cytokine and NGF expression, (3) LY303870 blocked fracture-induced epidermal thickening and BrdU incorporation after fracture, (4) anti-NGF antibody blocked SP-induced allodynia but not warmth or edema, and (5) LY303870 had no effect on bone microarchitecture. Collectively our data indicate that SP acting through NK1 receptors supports the nociceptive and vascular components of CRPS, but not the bone-related changes.
Literature
1.
go back to reference Sarangi PP, Ward AJ, Smith EJ, Staddon GE, Atkins RM: Algodystrophy and osteoporosis after tibial fractures. J Bone Joint Surg Br 1993, 75:450–452.PubMed Sarangi PP, Ward AJ, Smith EJ, Staddon GE, Atkins RM: Algodystrophy and osteoporosis after tibial fractures. J Bone Joint Surg Br 1993, 75:450–452.PubMed
2.
go back to reference Guo TZ, Offley SC, Boyd EA, Jacobs CR, Kingery WS: Substance P signaling contributes to the vascular and nociceptive abnormalities observed in a tibial fracture rat model of complex regional pain syndrome type I. Pain 2004, 108:95–107.CrossRefPubMed Guo TZ, Offley SC, Boyd EA, Jacobs CR, Kingery WS: Substance P signaling contributes to the vascular and nociceptive abnormalities observed in a tibial fracture rat model of complex regional pain syndrome type I. Pain 2004, 108:95–107.CrossRefPubMed
3.
go back to reference Groeneweg JG, Huygen FJ, Heijmans-Antonissen C, Niehof S, Zijlstra FJ: Increased endothelin-1 and diminished nitric oxide levels in blister fluids of patients with intermediate cold type complex regional pain syndrome type 1. BMC Musculoskelet Disord 2006, 7:91.CrossRefPubMedPubMedCentral Groeneweg JG, Huygen FJ, Heijmans-Antonissen C, Niehof S, Zijlstra FJ: Increased endothelin-1 and diminished nitric oxide levels in blister fluids of patients with intermediate cold type complex regional pain syndrome type 1. BMC Musculoskelet Disord 2006, 7:91.CrossRefPubMedPubMedCentral
4.
go back to reference Sabsovich I, Guo TZ, Wei T, Zhao R, Li X, Clark DJ, Geis C, Sommer C, Kingery WS: TNF signaling contributes to the development of nociceptive sensitization in a tibia fracture model of complex regional pain syndrome type I. Pain 2008, 137:507–519.CrossRefPubMed Sabsovich I, Guo TZ, Wei T, Zhao R, Li X, Clark DJ, Geis C, Sommer C, Kingery WS: TNF signaling contributes to the development of nociceptive sensitization in a tibia fracture model of complex regional pain syndrome type I. Pain 2008, 137:507–519.CrossRefPubMed
5.
go back to reference Sabsovich I, Wei T, Guo TZ, Zhao R, Shi X, Li X, Yeomans DC, Klyukinov M, Kingery WS, Clark JD: Effect of anti-NGF antibodies in a rat tibia fracture model of complex regional pain syndrome type I. Pain 2008, 138:47–60.CrossRefPubMedPubMedCentral Sabsovich I, Wei T, Guo TZ, Zhao R, Shi X, Li X, Yeomans DC, Klyukinov M, Kingery WS, Clark JD: Effect of anti-NGF antibodies in a rat tibia fracture model of complex regional pain syndrome type I. Pain 2008, 138:47–60.CrossRefPubMedPubMedCentral
6.
go back to reference Wei T, Sabsovich I, Guo TZ, Shi X, Zhao R, Li W, Geis C, Sommer C, Kingery WS, Clark DJ: Pentoxifylline attenuates nociceptive sensitization and cytokine expression in a tibia fracture rat model of complex regional pain syndrome. Eur J Pain 2009, 13:253–262.CrossRefPubMed Wei T, Sabsovich I, Guo TZ, Shi X, Zhao R, Li W, Geis C, Sommer C, Kingery WS, Clark DJ: Pentoxifylline attenuates nociceptive sensitization and cytokine expression in a tibia fracture rat model of complex regional pain syndrome. Eur J Pain 2009, 13:253–262.CrossRefPubMed
7.
go back to reference Li WW, Sabsovich I, Guo TZ, Zhao R, Kingery WS, Clark JD: The role of enhanced cutaneous IL-1beta signaling in a rat tibia fracture model of complex regional pain syndrome. Pain 2009, 144:303–313.CrossRefPubMedPubMedCentral Li WW, Sabsovich I, Guo TZ, Zhao R, Kingery WS, Clark JD: The role of enhanced cutaneous IL-1beta signaling in a rat tibia fracture model of complex regional pain syndrome. Pain 2009, 144:303–313.CrossRefPubMedPubMedCentral
8.
go back to reference Li WW, Guo TZ, Li XQ, Kingery WS, Clark JD: Fracture induces keratinocyte activation, proliferation, and expression of pro-nociceptive inflammatory mediators. Pain 2010, 151:843–852.CrossRefPubMedPubMedCentral Li WW, Guo TZ, Li XQ, Kingery WS, Clark JD: Fracture induces keratinocyte activation, proliferation, and expression of pro-nociceptive inflammatory mediators. Pain 2010, 151:843–852.CrossRefPubMedPubMedCentral
9.
go back to reference Weber M, Birklein F, Neundorfer B, Schmelz M: Facilitated neurogenic inflammation in complex regional pain syndrome. Pain 2001, 91:251–257.CrossRefPubMed Weber M, Birklein F, Neundorfer B, Schmelz M: Facilitated neurogenic inflammation in complex regional pain syndrome. Pain 2001, 91:251–257.CrossRefPubMed
10.
go back to reference Oyen WJ, Arntz IE, Claessens RM, Van der Meer JW, Corstens FH, Goris RJ: Reflex sympathetic dystrophy of the hand: an excessive inflammatory response? Pain 1993, 55:151–157.CrossRefPubMed Oyen WJ, Arntz IE, Claessens RM, Van der Meer JW, Corstens FH, Goris RJ: Reflex sympathetic dystrophy of the hand: an excessive inflammatory response? Pain 1993, 55:151–157.CrossRefPubMed
11.
go back to reference Leis S, Weber M, Isselmann A, Schmelz M, Birklein F: Substance-P-induced protein extravasation is bilaterally increased in complex regional pain syndrome. Exp Neurol 2003, 183:197–204.CrossRefPubMed Leis S, Weber M, Isselmann A, Schmelz M, Birklein F: Substance-P-induced protein extravasation is bilaterally increased in complex regional pain syndrome. Exp Neurol 2003, 183:197–204.CrossRefPubMed
12.
go back to reference Leis S, Weber M, Schmelz M, Birklein F: Facilitated neurogenic inflammation in unaffected limbs of patients with complex regional pain syndrome. Neurosci Lett 2004, 359:163–166.CrossRefPubMed Leis S, Weber M, Schmelz M, Birklein F: Facilitated neurogenic inflammation in unaffected limbs of patients with complex regional pain syndrome. Neurosci Lett 2004, 359:163–166.CrossRefPubMed
13.
go back to reference Weidner C, Klede M, Rukwied R, Lischetzki G, Neisius U, Skov PS, Petersen LJ, Schmelz M: Acute effects of substance P and calcitonin gene-related peptide in human skin–a microdialysis study. J Invest Dermatol 2000, 115:1015–1020.CrossRefPubMed Weidner C, Klede M, Rukwied R, Lischetzki G, Neisius U, Skov PS, Petersen LJ, Schmelz M: Acute effects of substance P and calcitonin gene-related peptide in human skin–a microdialysis study. J Invest Dermatol 2000, 115:1015–1020.CrossRefPubMed
14.
go back to reference Wei T, Li WW, Guo TZ, Zhao R, Wang L, Clark DJ, Oaklander AL, Schmelz M, Kingery WS: Post-junctional facilitation of Substance P signaling in a tibia fracture rat model of complex regional pain syndrome type I. Pain 2009, 144:278–286.CrossRefPubMedPubMedCentral Wei T, Li WW, Guo TZ, Zhao R, Wang L, Clark DJ, Oaklander AL, Schmelz M, Kingery WS: Post-junctional facilitation of Substance P signaling in a tibia fracture rat model of complex regional pain syndrome type I. Pain 2009, 144:278–286.CrossRefPubMedPubMedCentral
15.
go back to reference Guo TZ, Wei T, Kingery WS: Glucocorticoid inhibition of vascular abnormalities in a tibia fracture rat model of complex regional pain syndrome type I. Pain 2006, 121:158–167.CrossRefPubMed Guo TZ, Wei T, Kingery WS: Glucocorticoid inhibition of vascular abnormalities in a tibia fracture rat model of complex regional pain syndrome type I. Pain 2006, 121:158–167.CrossRefPubMed
16.
go back to reference Paus R, Heinzelmann T, Robicsek S, Czarnetzki BM, Maurer M: Substance P stimulates murine epidermal keratinocyte proliferation and dermal mast cell degranulation in situ. Arch Dermatol Res 1995, 287:500–502.CrossRefPubMed Paus R, Heinzelmann T, Robicsek S, Czarnetzki BM, Maurer M: Substance P stimulates murine epidermal keratinocyte proliferation and dermal mast cell degranulation in situ. Arch Dermatol Res 1995, 287:500–502.CrossRefPubMed
17.
go back to reference Tanaka T, Danno K, Ikai K, Imamura S: Effects of substance P and substance K on the growth of cultured keratinocytes. J Invest Dermatol 1988, 90:399–401.CrossRefPubMed Tanaka T, Danno K, Ikai K, Imamura S: Effects of substance P and substance K on the growth of cultured keratinocytes. J Invest Dermatol 1988, 90:399–401.CrossRefPubMed
18.
go back to reference Saade NE, Massaad CA, Ochoa-Chaar CI, Jabbur SJ, Safieh-Garabedian B, Atweh SF: Upregulation of proinflammatory cytokines and nerve growth factor by intraplantar injection of capsaicin in rats. J Physiol 2002, 545:241–253.CrossRefPubMedPubMedCentral Saade NE, Massaad CA, Ochoa-Chaar CI, Jabbur SJ, Safieh-Garabedian B, Atweh SF: Upregulation of proinflammatory cytokines and nerve growth factor by intraplantar injection of capsaicin in rats. J Physiol 2002, 545:241–253.CrossRefPubMedPubMedCentral
19.
go back to reference Zimmermann M: Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16:109–110.CrossRefPubMed Zimmermann M: Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16:109–110.CrossRefPubMed
20.
go back to reference Hongo JS, Laramee GR, Urfer R, Shelton DL, Restivo T, Sadick M, Galloway A, Chu H, Winslow JW: Antibody binding regions on human nerve growth factor identified by homolog- and alanine-scanning mutagenesis. Hybridoma 2000, 19:215–227.CrossRefPubMed Hongo JS, Laramee GR, Urfer R, Shelton DL, Restivo T, Sadick M, Galloway A, Chu H, Winslow JW: Antibody binding regions on human nerve growth factor identified by homolog- and alanine-scanning mutagenesis. Hybridoma 2000, 19:215–227.CrossRefPubMed
21.
go back to reference Halvorson KG, Kubota K, Sevcik MA, Lindsay TH, Sotillo JE, Ghilardi JR, Rosol TJ, Boustany L, Shelton DL, Mantyh PW: A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res 2005, 65:9426–9435.CrossRefPubMed Halvorson KG, Kubota K, Sevcik MA, Lindsay TH, Sotillo JE, Ghilardi JR, Rosol TJ, Boustany L, Shelton DL, Mantyh PW: A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res 2005, 65:9426–9435.CrossRefPubMed
22.
go back to reference Sevcik MA, Ghilardi JR, Peters CM, Lindsay TH, Halvorson KG, Jonas BM, Kubota K, Kuskowski MA, Boustany L, Shelton DL, Mantyh PW: Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain 2005, 115:128–141.CrossRefPubMed Sevcik MA, Ghilardi JR, Peters CM, Lindsay TH, Halvorson KG, Jonas BM, Kubota K, Kuskowski MA, Boustany L, Shelton DL, Mantyh PW: Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain 2005, 115:128–141.CrossRefPubMed
23.
go back to reference Shelton DL, Zeller J, Ho WH, Pons J, Rosenthal A: Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis. Pain 2005, 116:8–16.CrossRefPubMed Shelton DL, Zeller J, Ho WH, Pons J, Rosenthal A: Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis. Pain 2005, 116:8–16.CrossRefPubMed
24.
go back to reference Gitter BD, Bruns RF, Howbert JJ, Waters DC, Threlkeld PG, Cox LM, Nixon JA, Lobb KL, Mason NR, Stengel PW, et al.: Pharmacological characterization of LY303870: a novel, potent and selective nonpeptide substance P (neurokinin 1) receptor antagonist. J Pharmacol Exp Therapeut 1995, 275:737–744. Gitter BD, Bruns RF, Howbert JJ, Waters DC, Threlkeld PG, Cox LM, Nixon JA, Lobb KL, Mason NR, Stengel PW, et al.: Pharmacological characterization of LY303870: a novel, potent and selective nonpeptide substance P (neurokinin 1) receptor antagonist. J Pharmacol Exp Therapeut 1995, 275:737–744.
25.
go back to reference Hipskind PA, Howbert JJ, Bruns RF, Cho SSY, Crowell TA, Foreman MM, Gehlert DR, Iyengar S, Johnson KW, Krushinski JH, Li DL, Lobb KL, Mason NR, Muehl BS, Nixon JA, Phebus LA, Regoli D, Simmons RM, Threlkeld PG, Waters DC, Gitter BD: 3-Aryl-1,2,-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonists. J Med Chem 1996, 39:736–748.CrossRefPubMed Hipskind PA, Howbert JJ, Bruns RF, Cho SSY, Crowell TA, Foreman MM, Gehlert DR, Iyengar S, Johnson KW, Krushinski JH, Li DL, Lobb KL, Mason NR, Muehl BS, Nixon JA, Phebus LA, Regoli D, Simmons RM, Threlkeld PG, Waters DC, Gitter BD: 3-Aryl-1,2,-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonists. J Med Chem 1996, 39:736–748.CrossRefPubMed
26.
go back to reference Iyengar S, Hipskind PA, Gehlert DR, Schober D, Lobb KL, Nixon JA, Helton DR, Kallman MJ, Boucher S, Couture R, Li DL, Simmons RM: LY303870, a centrallyactive neurokinin-1 antagonist with a long duration of action. J Pharmacol Exp Ther 1997, 280:774–785.PubMed Iyengar S, Hipskind PA, Gehlert DR, Schober D, Lobb KL, Nixon JA, Helton DR, Kallman MJ, Boucher S, Couture R, Li DL, Simmons RM: LY303870, a centrallyactive neurokinin-1 antagonist with a long duration of action. J Pharmacol Exp Ther 1997, 280:774–785.PubMed
27.
go back to reference Kingery WS, Davies MF, Clark JD: A substance P receptor (NK1) antagonist can reverse vascular and nociceptive abnormalities in a rat model of complex regional pain syndrome type II. Pain 2003, 104:75–84.CrossRefPubMed Kingery WS, Davies MF, Clark JD: A substance P receptor (NK1) antagonist can reverse vascular and nociceptive abnormalities in a rat model of complex regional pain syndrome type II. Pain 2003, 104:75–84.CrossRefPubMed
28.
29.
go back to reference Schinkel C, Gaertner A, Zaspel J, Zedler S, Faist E, Schuermann M: Inflammatory mediators are altered in the acute phase of posttraumatic complex regional pain syndrome. Clin J Pain 2006, 22:235–239.CrossRefPubMed Schinkel C, Gaertner A, Zaspel J, Zedler S, Faist E, Schuermann M: Inflammatory mediators are altered in the acute phase of posttraumatic complex regional pain syndrome. Clin J Pain 2006, 22:235–239.CrossRefPubMed
30.
go back to reference de Mos M, Huygen FJ, Stricker BH, Dieleman JP, Sturkenboom MC: The association between ACE inhibitors and the complex regional pain syndrome: Suggestions for a neuro-inflammatory pathogenesis of CRPS. Pain 2009, 142:218–224.CrossRefPubMed de Mos M, Huygen FJ, Stricker BH, Dieleman JP, Sturkenboom MC: The association between ACE inhibitors and the complex regional pain syndrome: Suggestions for a neuro-inflammatory pathogenesis of CRPS. Pain 2009, 142:218–224.CrossRefPubMed
31.
go back to reference Kramer HH, He L, Lu B, Birklein F, Sommer C: Increased pain and neurogenic inflammation in mice deficient of neutral endopeptidase. Neurobiol Dis 2009, 35:177–183.CrossRefPubMed Kramer HH, He L, Lu B, Birklein F, Sommer C: Increased pain and neurogenic inflammation in mice deficient of neutral endopeptidase. Neurobiol Dis 2009, 35:177–183.CrossRefPubMed
32.
go back to reference Sahbaie P, Shi X, Guo TZ, Qiao Y, Yeomans DC, Kingery WS, Clark JD: Role of substance P signaling in enhanced nociceptive sensitization and local cytokine production after incision. Pain 2009, 145:341–349.CrossRefPubMedPubMedCentral Sahbaie P, Shi X, Guo TZ, Qiao Y, Yeomans DC, Kingery WS, Clark JD: Role of substance P signaling in enhanced nociceptive sensitization and local cytokine production after incision. Pain 2009, 145:341–349.CrossRefPubMedPubMedCentral
33.
go back to reference Dionne RA, Max MB, Gordon SM, Parada S, Sang C, Gracely RH, Sethna NF, MacLean DB: The substance P receptor antagonist CP-99,994 reduces acute postoperative pain. Clin Pharmacol Ther 1998, 64:562–568.CrossRefPubMed Dionne RA, Max MB, Gordon SM, Parada S, Sang C, Gracely RH, Sethna NF, MacLean DB: The substance P receptor antagonist CP-99,994 reduces acute postoperative pain. Clin Pharmacol Ther 1998, 64:562–568.CrossRefPubMed
34.
go back to reference Kingery WS: Role of neuropeptide, cytokine, and growth factor signaling in complex regional pain syndrome. Pain Med 2010, 11:1239–1250.CrossRefPubMed Kingery WS: Role of neuropeptide, cytokine, and growth factor signaling in complex regional pain syndrome. Pain Med 2010, 11:1239–1250.CrossRefPubMed
35.
go back to reference Malik-Hall M, Dina OA, Levine JD: Primary afferent nociceptor mechanisms mediating NGF-induced mechanical hyperalgesia. Eur J Neurosci 2005, 21:3387–3394.CrossRefPubMed Malik-Hall M, Dina OA, Levine JD: Primary afferent nociceptor mechanisms mediating NGF-induced mechanical hyperalgesia. Eur J Neurosci 2005, 21:3387–3394.CrossRefPubMed
36.
go back to reference Cattaneo A: Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain. Curr Opin Mol Ther 2010, 12:94–106.PubMed Cattaneo A: Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain. Curr Opin Mol Ther 2010, 12:94–106.PubMed
37.
go back to reference Lane NE, Schnitzer TJ, Birbara CA, Mokhtarani M, Shelton DL, Smith MD, Brown MT: Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 2010, 363:1521–1531.CrossRefPubMed Lane NE, Schnitzer TJ, Birbara CA, Mokhtarani M, Shelton DL, Smith MD, Brown MT: Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 2010, 363:1521–1531.CrossRefPubMed
38.
go back to reference Schnitzer TJ, Lane NE, Birbara C, Smith MD, Simpson SL, Brown MT: Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthr Cartil 2011, 19:639–646.CrossRefPubMed Schnitzer TJ, Lane NE, Birbara C, Smith MD, Simpson SL, Brown MT: Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthr Cartil 2011, 19:639–646.CrossRefPubMed
39.
go back to reference Katz N, Borenstein DG, Birbara C, Bramson C, Nemeth MA, Smith MD, Brown MT: Efficacy and safety of tanezumab in the treatment of chronic low back pain. Pain 2011, 152:2248–2258.CrossRefPubMed Katz N, Borenstein DG, Birbara C, Bramson C, Nemeth MA, Smith MD, Brown MT: Efficacy and safety of tanezumab in the treatment of chronic low back pain. Pain 2011, 152:2248–2258.CrossRefPubMed
40.
go back to reference Zhao P, Barr TP, Hou Q, Dib-Hajj SD, Black JA, Albrecht PJ, Petersen K, Eisenberg E, Wymer JP, Rice FL, Waxman SG: Voltage-gated sodium channel expression in rat and human epidermal keratinocytes: evidence for a role in pain. Pain 2008, 139:90–105.CrossRefPubMed Zhao P, Barr TP, Hou Q, Dib-Hajj SD, Black JA, Albrecht PJ, Petersen K, Eisenberg E, Wymer JP, Rice FL, Waxman SG: Voltage-gated sodium channel expression in rat and human epidermal keratinocytes: evidence for a role in pain. Pain 2008, 139:90–105.CrossRefPubMed
41.
go back to reference Hou Q, Barr T, Gee L, Vickers J, Wymer J, Borsani E, Rodella L, Getsios S, Burdo T, Eisenberg E, Guha U, Lavker R, Kessler J, Chittur S, Fiorino D, Rice F, Albrecht P: Keratinocyte expression of calcitonin gene-related peptide beta: implications for neuropathic and inflammatory pain mechanisms. Pain 2011, 152:2036–2051.CrossRefPubMedPubMedCentral Hou Q, Barr T, Gee L, Vickers J, Wymer J, Borsani E, Rodella L, Getsios S, Burdo T, Eisenberg E, Guha U, Lavker R, Kessler J, Chittur S, Fiorino D, Rice F, Albrecht P: Keratinocyte expression of calcitonin gene-related peptide beta: implications for neuropathic and inflammatory pain mechanisms. Pain 2011, 152:2036–2051.CrossRefPubMedPubMedCentral
42.
go back to reference Urban LA, Fox AJ: NK1 receptor antagonists–are they really without effect in the pain clinic? Trends Pharmacol Sci 2000, 21:462–464. author reply 465CrossRefPubMed Urban LA, Fox AJ: NK1 receptor antagonists–are they really without effect in the pain clinic? Trends Pharmacol Sci 2000, 21:462–464. author reply 465CrossRefPubMed
Metadata
Title
Keratinocyte expression of inflammatory mediators plays a crucial role in substance P-induced acute and chronic pain
Authors
Tzuping Wei
Tian-Zhi Guo
Wen-Wu Li
Saiyun Hou
Wade S Kingery
John David Clark
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2012
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/1742-2094-9-181

Other articles of this Issue 1/2012

Journal of Neuroinflammation 1/2012 Go to the issue